"In less than 10 years, CEPI has helped to redefine how the world develops vaccines for emerging infectious diseases, shifting from reactive crisis response to collaborative preparedness." - Dr Tedros Adhanom Ghebreyesus. A powerful endorsement of CEPI 3.0 from our @who.int partners.

Our February newsletter is live! It spotlights the launch of CEPI 3.0 Investment Case and Strategy. Inside, you’ll find a deep dive into our next strategic phase, messages of support, a dedicated reading corner and more.

A great video from our partners on the impact that CEPI's funding is having on clinical trial preparedness in the West Africa region ⬇️

Epidemics & pandemics are a defining #HealthSecurity challenge of our time. @cepi.net#HealthSecurityis working to transform the way we tackle today’s viral threats and get ahead of tomorrow’s. CEPI's 3.0 strategy aims to secure a safer, better prepared future for all: https://bit.ly/4cFE2y9 #SecureTheFuture

The Biospecimen Sourcing Initiative aims to facilitate the timely and ethical collection of biological samples during an outbreak: https://bit.ly/4qILZWZ Biospecimens from survivors are necessary for the rapid development of new vaccines, treatments & diagnostics. #100DaysMission @cepi.net

A new All Africa feature highlights both the progress made against Ebola — and the work still ahead — drawing on insights from CEPI CEO Richard Hatchett.

In mid-2025, CEPI welcomed its second cohort of Global South Fellows. Now, halfway through the year-long fellowship, we caught up with Dr Umar Ahmad—one of the Fellows embedded in CEPI’s Laboratory Research and Innovations department—to discuss his experience. Read the Q&A blog to learn more ⬇️

Promising Lassa vaccine candidates are in clinical development, one of which could be licensed in the next decade. ✏️We must start planning now to translate this progress into protection, write CEPI's Oyeronke Oyebanji and WAHO's Virgil Lokossou in @projectsyndicate.bsky.social:

As we build momentum for CEPI 3.0 (2027–2031), we’re sharing messages from across our Coalition, showing why investment is key to securing the future from epidemic and pandemic threats. Below, Gavi CEO Dr Sania Nishtar shares her support and how our organisations collaborate to protect everyone.

“We invest in CEPI because it makes Norway safer, and it makes the world safer” — Jonas Gahr Støre, Prime Minister of Norway. In a new message marking the launch of our CEPI 3.0 Investment Case, Norway’s Prime Minister underscores why sustained investment in CEPI matters, nationally and globally.

Today marks the launch of the CEPI 3.0 Investment Case and Strategy. CEPI 3.0 – our 2027-2031 strategy - is the next step in CEPI’s mission to transform the way the world tackles epidemic and pandemic threats. Discover more in the press release ⬇️

At #MSC2026, CEPI is partnering with @ForeignPolicy to host an official side event on the #100DaysMission—bringing science, policy & security together to accelerate responses to future biological threats. 📍 Munich | 🗓️ 14 Feb | ⏰ 09:30 CET 🔗 Request to attend in person or online:

This week CEPI is hosting a fictional pandemic simulation exercise in Seoul with Korea's Ministry of Food Drug & Safety, the Korea Disease Control and Prevention Agency and IVI. The expert meeting will explore opportunities to strengthen Korea's readiness to rapidly respond to a future viral threat⤵️

📣💡 With the prospect of protection against Lassa fever closer than ever before, CEPI and the West African Health Organization (WAHO) have launched the first end-to-end access roadmap for Lassa fever vaccines. Read more:

Samsung Biologics becomes the latest organisation to join CEPI's Vaccine Manufacturing Facility Network (VMFN) -- a globally distributed manufacturing ecosystem designed to enable rapid and equitable access to vaccines in future pandemics. More: cepi.net/cepi-and-sam...

Check out CEPI's first newsletter of 2026 🗞️ This month spotlights new partnerships to expand access to Ebola vaccines. It also includes our latest R&D and manufacturing news and all the other regular features. www.linkedin.com/pulse/closin...

The 100 Days Mission 5th Implementation Report is now available. The report, produced by @ippsecretariat.org, reflects a pivotal year for pandemic preparedness, reviewing recent progress and setting out priorities for 2026. 📘 bit.ly/100dm-5th-re...

AI is becoming a critical tool in how the world responds to infectious disease threats. In a new WEF blog, CEPI CEO Richard Hatchett and Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen explore how AI-enabled platforms can help close the gap between pathogen detection & vaccine development.

Are you attending the 2026 @MunSecConf? If so, be sure to add CEPI and Foreign Policy's official side event to your list: The 100 Days Mission: Defending Against Pandemic and Biological Risks in a Fragmented World ⬇️ foreignpolicy.com/events/fp-ms...

A new @el_pais article explores how Africa is strengthening its end-to-end vaccine development to build vaccine sovereignty and respond faster to future outbreaks, featuring insights from CEPI’s Amadou Sall. Read more: elpais.com/planeta-futu...

“Standardized clinical assays, diagnostic assays and, ultimately, a vaccine are needed to prepare for future Nipah virus outbreaks.” A CEPI-led publication in @Nature Health explores what the world needs to respond effectively to #Nipah outbreaks. www.nature.com/articles/s44...

🎙️ How do you stop a pandemic before it starts? CEPI’s Valentina Bernasconi and Charles River’s Marie-Eve Poupart break it down: vaccines, lab tools & preparpring for a Disease X. Listen to the full podcast: www.criver.com/eureka/plann...

Our new short communication in Vaccine outlines CEPI’s Coronavirus Vaccine Library: a preparedness effort to build and share antigen designs, assays and data across priority coronaviruses. Read in full: sciencedirect.com/science/arti...

Amid a Rift Valley fever outbreak in West Africa, the Nuffield Department of Medicine @ox.ac.uk and Serum Institute of India have entered into a $3.5m agreement supported by CEPI to create the world’s largest reserve of Oxford’s investigational Rift Valley fever vaccine💉

Can scientists design an all-in-one vaccine to protect against multiple deadly viruses, including Ebola, Sudan and Marburg? @ox.ac.uk and partners, including the University of Leipzig and Moderna, are leading a new project with $26.7m from CEPI and @horizoneu.bsky.social. cepi.net/ambitious-re...

AI is revolutionising how science can protect the world and its people against the threat of infectious disease outbreaks. Learn how CEPI is harnessing the power of AI to transform vaccine development for future epidemics or pandemics. https://cepi.net/artificial-intelligence

CEPI’s Biosecurity Strategy—supported by funding from Global Affairs Canada—aims to bolster global health security, underscoring its commitment to tackling emerging epidemic and pandemic threats, whether they arise naturally, accidentally or through deliberate misuse. https://cepi.net/biosecurity

ICYMI: Check out CEPI CEO Dr Richard Hatchett's 2025 end of year reflections. https://bit.ly/49iV573

The viruses that put humanity at greatest risk to date come from 25 or so virus families. It is these families that are most likely to produce the next deadly viral threat. https://bit.ly/3EUmaAN

To date, CEPI has made investments in over 75 vaccine candidates or platform technologies. This includes advancing research against: 🔵 COVID-19 🔵 MERS 🔵 Nipah 🔵 Lassa fever 🔵 Chikungunya 🔵 Rift Valley fever 🔵 Disease X 🔵 Ebola Find out more 👇https://cepi.net/priority-pathogens

What if it took 100 days to make a safe and effective vaccine against any virus? We could stay one step ahead of infectious diseases and outbreaks could be stopped before they ever spiralled into pandemics #100DaysMission https://cepi.net/cepi-20-and-100-days-mission

The Biospecimen Sourcing Initiative is a new global resource that aims to facilitate the timely, coordinated and ethical sourcing of biospecimens in an outbreak. Specimens provide scientists with insights into the virus and how the body fends off an infection ⤵️ @path.org cepi.net/disease-outb...

🚨 Exciting news for global health security: CEPI is supporting a pivotal Phase 3 trial to advance Moderna’s mRNA H5 pandemic influenza vaccine candidate (mRNA-1018) towards licensure and enable rapid, equitable access in the event of a flu pandemic.

🚨 Exciting news for global health security: CEPI is supporting a pivotal Phase 3 trial to advance Moderna’s mRNA H5 pandemic influenza vaccine candidate (mRNA-1018) towards licensure and enable rapid, equitable access in the event of a flu pandemic.

In our Innovation for Impact story, we spoke with icddr,b’s Dr K Zaman and CEPI’s Nipah programme lead, Rick Jarman, to explore the impact of CEPI's $150 million Nipah R&D portfolio and how it's helping the world prepare to confront one of the most lethal viral threats.

CEPI is backing a second $198,000 project with GENSPEED Biotech to speed up vaccine quality testing. The rapid, automated assay can detect residual proteins in ~20 minutes—far faster than today’s 3-hour methods.

📢 A world first: CEPI-funded Nipah virus vaccine candidate enters Phase II clinical trials. The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.

During a disease outbreak, #VaccineDevelopment efforts rely on biological samples from survivors. With @cepi.net#VaccineDevelopment we conducted a simulation exercise to test the design and development of a new network that aims to collect and share these samples consistently and equitably: https://bit.ly/440DQ7O

The first volunteer has received a dose in a first-in-human trial of Oxford’s Lassa vaccine, marking a major milestone in the fight against the deadly virus. Find out more ⬇️ @ovg.ox.ac.uk | @cepi.net

📢 A world first: CEPI-funded Nipah virus vaccine candidate enters Phase II clinical trials. The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.

📣 The Republic of Korea's Ministry of Foreign Affairs has announced new $18.9 million support to CEPI to bolster efforts to protect against the next deadly pandemic and boost international health security 🇰🇷 cepi.net/korea-steps-...

📣The first volunteer has received a dose of @ox.ac.uk's Lassa fever vaccine candidate in a Phase I trial funded by CEPI. The deadly haemmorhagic fever causes annual outbreaks across West Africa, however no vaccine is currently available for use (1/2).

Last month, CEPI had the pleasure of welcoming Marjolijn Sonnema, Vice Minister of Health of the Netherlands, to The Aurum Institute in Johannesburg.

CEPI’s November newsletter is out! 🗞️ This edition spotlights recent regulatory “pressure test” simulations in Brasilia and Mombasa, early clinical progress on a Lassa fever vaccine, new partnerships to speed up vaccine manufacturing and release, and lots more. www.linkedin.com/pulse/pressu...

CEPI’s new publication lays out the blueprint for equitable access at the heart of the organisation’s outbreak R&D. Our Pathogen Archetype Frameworks details four pathogen archetypes, which ultimately guide CEPI’s access funding, advocacy, and catalysing efforts. Learn more in the blog ⬇️

Join WAHO, CEPI & partners for a webinar launching the Lassa Fever Research Agenda & open-access Repository—key tools to guide research, inform policy, and support timely, equitable vaccine introduction. 📅 25 Nov | 🕛 12:00 GMT 🔗 Register: bit.ly/4i8pYxT

A new CEPI-funded initiative with LumaCyte and IDT Biologika aims to overcome a major hurdle in vaccine manufacturing: the slow, complex process of potency testing.

The Regionalized Vaccine Manufacturing Collaborative (RVMC) has released its first Status Report - a major step toward building sustainable, regionally-led vaccine manufacturing across Africa, Southeast Asia, and Latin America and the Caribbean.

Sterility testing — ensuring vaccine batches are free from microbial contamination — can take up to a month. With new CEPI funding of up to $199,238, USA-based CBio will develop a rapid sterility testing system based on its cellPhoresis™ technology.

The West African Health Organization(WAHO), with support from CEPI and other partners, have launched the first-ever Lassa Fever Vaccine Policy Research Agenda. Read in full: bit.ly/4nTNVdO